Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
05 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/05/3213173/0/en/Apogee-Therapeutics-to-Host-Conference-Call-to-Report-Interim-Results-from-the-Phase-1b-Trial-of-APG777-in-Patients-with-Mild-to-Moderate-Asthma-and-2026-Anticipated-Milestones-on-.html
10 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/10/3184408/0/en/Apogee-Therapeutics-Provides-Pipeline-Progress-and-Reports-Third-Quarter-2025-Financial-Results.html
10 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/10/3184340/0/en/Apogee-Therapeutics-Announces-Positive-Interim-Phase-1-Results-from-Healthy-Volunteer-Trial-of-APG333-its-Novel-Half-Life-Extended-TSLP-Antibody.html
10 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/10/3165093/0/en/Apogee-Therapeutics-Inc-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares-for-Gross-Proceeds-of-345-Million.html
08 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/09/3163822/0/en/Apogee-Therapeutics-Inc-Announces-Pricing-of-300-Million-Underwritten-Public-Offering.html
08 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/08/3163716/0/en/Apogee-Therapeutics-Inc-Announces-Proposed-Underwritten-Public-Offering.html
Drugs in Development
Details:
The proceeds from the offering will be used to fund the clinical development of APG777, an antibody targeting IL-13 receptor for inflammatory and immunology markets.
Lead Product(s): APG777
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Jefferies | BofA Securities | Guggenheim Securities | TD Cowen
Deal Size: $345.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 10, 2025
Lead Product(s) : APG777
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Jefferies | BofA Securities | Guggenheim Securities | TD Cowen
Deal Size : $345.0 million
Deal Type : Public Offering
Apogee Therapeutics Announces Closing of Public Offering, Raises $345M
Details : The proceeds from the offering will be used to fund the clinical development of APG777, an antibody targeting IL-13 receptor for inflammatory and immunology markets.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 10, 2025
Details:
In the public offering, APG777, an unconjugated antibody targeting IL-13 receptor, aims to advance in the inflammatory and immunology (I&I) space.
Lead Product(s): APG777
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: APG777
Study Phase: PreclinicalProduct Type: Antibody, Unconjugated
Sponsor: Jefferies
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 08, 2025
Lead Product(s) : APG777
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $300.0 million
Deal Type : Public Offering
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
Details : In the public offering, APG777, an unconjugated antibody targeting IL-13 receptor, aims to advance in the inflammatory and immunology (I&I) space.
Product Name : APG777
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 08, 2025
Details:
In the public offering, APG777, an unconjugated antibody targeting IL-13 receptor, aims to advance in the inflammatory and immunology (I&I) markets.
Lead Product(s): APG777
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: APG777
Study Phase: PreclinicalProduct Type: Antibody, Unconjugated
Sponsor: Jefferies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering October 08, 2025
Lead Product(s) : APG777
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Jefferies
Deal Size : Undisclosed
Deal Type : Public Offering
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
Details : In the public offering, APG777, an unconjugated antibody targeting IL-13 receptor, aims to advance in the inflammatory and immunology (I&I) markets.
Product Name : APG777
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 08, 2025
Details:
APG777 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Dermatitis, Atopic.
Lead Product(s): APG777,APG990
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 18, 2025
Lead Product(s) : APG777,APG990
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Study of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
Details : APG777 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 18, 2025
Details:
APG777 is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Dermatitis, Atopic.
Lead Product(s): APG777
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 04, 2025
Lead Product(s) : APG777
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Details : APG777 is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 04, 2025
Details:
APG808 is a novel half-life extended IL-4Rα antibody, which is currently being evaluated for the treatment of mild-to-moderate asthma.
Lead Product(s): APG808
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 12, 2025
Lead Product(s) : APG808
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Apogee Shows Interim Success in Phase 1b Trial of APG808 for Asthma
Details : APG808 is a novel half-life extended IL-4Rα antibody, which is currently being evaluated for the treatment of mild-to-moderate asthma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2025
Details:
APG777 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Lead Product(s): APG777
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2025
Lead Product(s) : APG777
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APG777 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 10, 2025
Details:
APG990 is a novel, SQ, half-life extended mAb targeting OX40L
Lead Product(s): APG990
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 03, 2025
Lead Product(s) : APG990
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Apogee's APG990 Phase 1 Shows Potential for 3- & 6-Month Maintenance Dosing
Details : APG990 is a novel, SQ, half-life extended mAb targeting OX40L
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 03, 2025
Details:
APG777 is a IL-13 inhibitor antibody candidate, which is being evaluated in clinical trial studies for the treatment of patients with atopic dermatitis.
Lead Product(s): APG777
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2025
Lead Product(s) : APG777
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Apogee Doses First Patient in Part B of Phase 2 APEX Trial for APG777 in Atopic Dermatitis
Details : APG777 is a IL-13 inhibitor antibody candidate, which is being evaluated in clinical trial studies for the treatment of patients with atopic dermatitis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 03, 2025
Details:
APG333 is a novel, SQ extended half-life mAb targeting TSLP, a key driver of Type 2 and Type 3 inflammation in eosinophilic and non-eosinophilic conditions, like asthma, COPD.
Lead Product(s): APG333
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 10, 2024
Lead Product(s) : APG333
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Apogee Doses First Participants in Phase 1 APG333 Trial for Respiratory Conditions
Details : APG333 is a novel, SQ extended half-life mAb targeting TSLP, a key driver of Type 2 and Type 3 inflammation in eosinophilic and non-eosinophilic conditions, like asthma, COPD.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 10, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
